ANDA 214008, held by Natco. Tipiracil Hydrochloride; Trifluridine.
As of Nov 22, 2026, ANDA 214008 (Tipiracil Hydrochloride and Trifluridine), held by Natco, was first approved by FDA on Jun 13, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2023 | Original application | Approved |
| Tipiracil Hydrochloride and TrifluridineEQ 6.14MG BASE;15MG · tablet;oral | Tipiracil Hydrochloride; Trifluridine | Rx |
| Tipiracil Hydrochloride and TrifluridineEQ 8.19MG BASE;20MG · tablet;oral | Tipiracil Hydrochloride; Trifluridine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters